These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 31842958)

  • 41. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.
    Bahrami A; Hesari A; Khazaei M; Hassanian SM; Ferns GA; Avan A
    J Cell Physiol; 2018 Mar; 233(3):2162-2169. PubMed ID: 28407239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
    Haagensen EJ; Thomas HD; Wilson I; Harnor SJ; Payne SL; Rennison T; Smith KM; Maxwell RJ; Newell DR
    PLoS One; 2013; 8(12):e81763. PubMed ID: 24339963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of
    Mésange P; Bouygues A; Ferrand N; Sabbah M; Escargueil AE; Savina A; Chibaudel B; Tournigand C; André T; de Gramont A; Larsen AK
    Clin Cancer Res; 2018 Jun; 24(11):2548-2558. PubMed ID: 29490990
    [No Abstract]   [Full Text] [Related]  

  • 46. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
    Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
    Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer.
    Cardone C; Blauensteiner B; Moreno-Viedma V; Martini G; Simeon V; Vitiello PP; Ciardiello D; Belli V; Matrone N; Troiani T; Morgillo F; Zito Marino F; Dentice M; Nappi A; Boccaccino A; Antoniotti C; Cremolini C; Pietrantonio F; Prager GW; Normanno N; Maiello E; Argiles G; Elez E; Signoriello G; Franco R; Falcone A; Tabernero J; Sibilia M; Ciardiello F; Martinelli E
    Eur J Cancer; 2020 Oct; 138():1-10. PubMed ID: 32818762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
    She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
    [No Abstract]   [Full Text] [Related]  

  • 50. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
    Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
    Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRAF
    Feng D; Qin B; Pal K; Sun L; Dutta S; Dong H; Liu X; Mukhopadhyay D; Huang S; Sinicrope FA
    Oncogene; 2019 Oct; 38(41):6752-6766. PubMed ID: 31406255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
    Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
    Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
    Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
    J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q; Sun X; Guo H; Yu Q
    Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
    Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.